{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:20:21Z","timestamp":1783592421464,"version":"3.55.0"},"reference-count":50,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.69777\/370269"],"award-info":[{"award-number":["https:\/\/doi.org\/10.69777\/370269"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","award":["AUDACE programme"],"award-info":[{"award-number":["AUDACE programme"]}],"id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds d\u2019enseignement et de recherche"},{"DOI":"10.13039\/100008700","name":"Centre de recherche sur le cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliat Med"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening illnesses, implementing this intervention into palliative care settings presents significant real-world challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To examine palliative care stakeholders\u2019 knowledge and attitudes regarding psilocybin-assisted therapy, and identify barriers and facilitators to its implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We conducted a cross-sectional online survey between April 15 and December 18, 2024. The survey assessed perceived knowledge, attitudes, and perceived barriers and facilitators to the effective integration of psilocybin-assisted therapy into palliative care settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting\/participants:<\/jats:title>\n                    <jats:p>One hundred and twenty-one adults involved in palliative care (physicians, other healthcare professionals, caregivers, and managers) were recruited from Canada\u2019s four most populous provinces: Qu\u00e9bec, Ontario, Alberta, and British Columbia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-three percent of stakeholders reported having good knowledge of psilocybin\u2019s potential benefits and risks. Attitudes towards psilocybin-assisted therapy were predominantly non-favourable (61%), yet varied across occupational groups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), with 95% of physicians reporting favourable attitudes. The lack of trained healthcare providers was viewed as the primary barrier to implementation. Key facilitators included further research and developing standardised intervention protocols. Sixty-eight percent\u2009of stakeholders endorsed the introduction of psilocybin-assisted therapy during the early stages of the illness trajectory.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Translating the potential of psilocybin-assisted therapy for existential distress from clinical trials into palliative care settings requires careful consideration and collaboration with stakeholders. Given the significant divergence in perspectives between clinical and non-clinical groups, tailored interprofessional education could help build shared understanding and support effective implementation. Being conducted in Canada, transferability to different regulatory frameworks may be limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02692163261446141","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:37:15Z","timestamp":1779205035000},"page":"1047-1058","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3063-7545","authenticated-orcid":false,"given":"Louis","family":"Plourde","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 Laval, QC, Canada"},{"name":"Oncology Division, CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Centre, QC, Canada"},{"name":"R\u00e9seau qu\u00e9b\u00e9cois de recherche en soins palliatifs et de fin de vie (RQSPAL),\u2009QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3440-4102","authenticated-orcid":false,"given":"Sue-Ling","family":"Chang","sequence":"additional","affiliation":[{"name":"Oncology Division, CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Centre, QC, Canada"},{"name":"R\u00e9seau qu\u00e9b\u00e9cois de recherche en soins palliatifs et de fin de vie (RQSPAL),\u2009QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8335-3773","authenticated-orcid":false,"given":"Olivia","family":"Nguyen","sequence":"additional","affiliation":[{"name":"R\u00e9seau qu\u00e9b\u00e9cois de recherche en soins palliatifs et de fin de vie (RQSPAL),\u2009QC, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"CIUSSS Nord-de-l\u2019\u00cele-de-Montr\u00e9al,\u2009QC, Canada"},{"name":"Soci\u00e9t\u00e9 qu\u00e9b\u00e9coise des m\u00e9decins de soins palliatifs (SQMDSP), Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-9943","authenticated-orcid":false,"given":"Nicolas","family":"Garel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Addictology, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al Research Centre (CRCHUM),\u2009QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4095-3596","authenticated-orcid":false,"given":"Houman","family":"Farzin","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC, Canada"},{"name":"Faculty of Medicine and Health Sciences, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7376-208X","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Stephan","sequence":"additional","affiliation":[{"name":"Private Practice, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2300-1335","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Fallu","sequence":"additional","affiliation":[{"name":"School of Psychoeducation, Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Center for Public Health Research (CReSP), Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3207-8211","authenticated-orcid":false,"given":"Michel","family":"Dorval","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 Laval, QC, Canada"},{"name":"Oncology Division, CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Centre, QC, Canada"},{"name":"R\u00e9seau qu\u00e9b\u00e9cois de recherche en soins palliatifs et de fin de vie (RQSPAL),\u2009QC, Canada"},{"name":"CISSS Chaudi\u00e8re-Appalaches Research Center, L\u00e9vis, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"P3A Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119897615"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00020"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i7.908"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2025.08.001"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70002-X"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4872"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2022.08.002"},{"key":"e_1_3_3_13_2","article-title":"Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases","volume":"9","author":"Schipper S","year":"2024","unstructured":"Schipper S, Nigam K, Schmid Y, et al. Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. Cochrane Database Syst Rev 2024; 9: CD015383.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Nutt DJ Hunt P Schlag AK et al. The Australia story: current status and future challenges for the clinical applications of psychedelics. Br J Pharmacol 2024: 1\u201310. https:\/\/doi.org\/10.1111\/bph.17398","DOI":"10.1111\/bph.17398"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66817-0"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Aicher H Duffour C Liechti M et al. Treatment recommendations psychedelic-assisted therapy (PAT). Swiss Society for Addiction Medicine https:\/\/www.swisshealthweb.ch\/fileadmin\/assets\/SANP\/2024\/sanp.2024.1488043038\/Treatment_recommendations_PAT.pdf (2024 accessed 25 June 2025).","DOI":"10.4414\/sanp.2024.1488043038"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.4101"},{"key":"e_1_3_3_18_2","unstructured":"Benda M. Amendment to the government bill amending act no. 40\/2009 Coll. the criminal code. Parliamentary Press 861 https:\/\/psychedelicalpha.com\/wp-content\/uploads\/2025\/06\/Czech-Psilocybin-Amendment-Machine-Translated.pdf (2025 accessed 25 June 2025)."},{"key":"e_1_3_3_19_2","unstructured":"MacDuff K. Psychiatrist hopes \u2018magic mushroom\u2019 treatment will be more widely available. RNZ https:\/\/www.rnz.co.nz\/news\/national\/564556\/psychiatrist-hopes-magic-mushroom-treatment-will-be-more-widely-available (2025 accessed 25 June 2025)."},{"key":"e_1_3_3_20_2","unstructured":"Hardman J. Germany establishes EU\u2019s first psilocybin compassionate access program. Psychedelic Alpha https:\/\/psychedelicalpha.com\/news\/germany-establishes-eus-first-psilocybin-compassionate-access-program (2025 accessed 25 June 2025)."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2025.11.007"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0549"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2020.0764"},{"key":"e_1_3_3_24_2","first-page":"153","article-title":"Roadmap for equitable access and responsible use of psilocybin-assisted psychotherapy in palliative care","volume":"6","author":"Dorval M","year":"2025","unstructured":"Dorval M, Chang SL, Farzin H, et al. Roadmap for equitable access and responsible use of psilocybin-assisted psychotherapy in palliative care. Palliat -med Rep 2025; 6: 153\u2013160.","journal-title":"Palliat -med Rep"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000113"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114555249"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0036"},{"key":"e_1_3_3_29_2","article-title":"Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals","volume":"14","author":"Wang E","year":"2024","unstructured":"Wang E, Mathai DS, Gukasyan N, et al. Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Sci Rep 2024; 14: 28022.","journal-title":"Sci Rep"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/jpm.13141"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000828"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.1971343"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/00048674251346679"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951522001481"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.1916659"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-021-00889-x"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18158160"},{"key":"e_1_3_3_38_2","unstructured":"Health Canada. Special Access Program for drugs: guidance document for industry and practitioners. Health Canada https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/special-access-drugs\/guidance-document.html (2022 accessed 25 June 2025)."},{"key":"e_1_3_3_39_2","unstructured":"Government of Canada. Regulations amending certain regulations relating to restricted drugs (Special Access Program): SOR\/2021-271. Canada Gazette Part II. https:\/\/www.gazette.gc.ca\/rp-pr\/p2\/2022\/2022-01-05\/html\/sor-dors271-eng.html (2022 accessed 25 June 2025)."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-025-00446-y"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-022-00468-0"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.04.025"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-021-01181-5"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-010-0319-7"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/02692163231222430"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.14650"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-025-06871-y"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.1957183"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1083-6101.2005.tb00259.x"}],"container-title":["Palliative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02692163261446141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02692163261446141","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02692163261446141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:43:35Z","timestamp":1783590215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02692163261446141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/02692163261446141"],"URL":"https:\/\/doi.org\/10.1177\/02692163261446141","relation":{},"ISSN":["0269-2163","1477-030X"],"issn-type":[{"value":"0269-2163","type":"print"},{"value":"1477-030X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}